↓ Skip to main content

American Association for Cancer Research

Article Metrics

Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial

Overview of attention for article published in Clinical Cancer Research, February 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
18 news outlets
twitter
19 tweeters

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
18 Mendeley
Title
Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial
Published in
Clinical Cancer Research, February 2020
DOI 10.1158/1078-0432.ccr-19-4000
Pubmed ID
Authors

Ming Lu, Panpan Zhang, Yanqiao Zhang, Zhongwu Li, Ji-fang Gong, Jie Li, Jian Li, Yan Li, Xiaotian Zhang, ZhiHao Lu, Xicheng Wang, Jun Zhou, Zhi Peng, Weifeng Wang, Hui Feng, Hai Wu, Sheng Yao, Lin Shen

Twitter Demographics

The data shown below were collected from the profiles of 19 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 17%
Researcher 3 17%
Student > Bachelor 3 17%
Professor 1 6%
Student > Master 1 6%
Other 2 11%
Unknown 5 28%
Readers by discipline Count As %
Medicine and Dentistry 8 44%
Biochemistry, Genetics and Molecular Biology 3 17%
Economics, Econometrics and Finance 1 6%
Agricultural and Biological Sciences 1 6%
Unknown 5 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 136. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2021.
All research outputs
#193,077
of 19,019,810 outputs
Outputs from Clinical Cancer Research
#72
of 11,607 outputs
Outputs of similar age
#5,772
of 273,628 outputs
Outputs of similar age from Clinical Cancer Research
#3
of 154 outputs
Altmetric has tracked 19,019,810 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,607 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,628 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 154 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.